RIGEL PHARMACEUTICALS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $367.0M | $17.5M | $-25.1M | $-58.6M | $-17.9M | $-29.7M | $-66.9M | $-70.5M |
| Depreciation & Amortization | $2.4M | $2.2M | $1.2M | $998.0K | $1.2M | $706.0K | $683.0K | $594.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $2.4M | $2.1M | $1.1M | $100.0K | — | — | — | — |
| Stock-Based Compensation | $12.7M | $12.4M | $8.8M | $12.4M | $9.5M | $7.3M | $9.1M | $7.7M |
| Net Cash from Operating Activities | $75.7M | $31.5M | $-5.7M | $-73.8M | $5.9M | $-52.2M | $-41.5M | $-58.8M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | $450.0K | $627.0K | $1.3M | $1.5M | $1.1M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-92.4M | $4.1M | $-4.3M | $72.8M | $-80.0M | $47.5M | $-23.7M | $25.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $601.0K | $-11.6M | $18.4M | $6.6M | $62.7M | $12.6M | $11.4M | $71.9M |
| Net Change in Cash | — | — | — | — | — | — | — | $38.0M |
| Free Cash Flow | — | — | — | $-74.2M | $5.3M | $-53.4M | $-43.0M | $-59.9M |